Current developments in dual antiplatelet therapy after stenting

Minerva Cardioangiologica

Volumn 62, Issue 3, 2014, Pages 261-276

  Giacoppo, D ^a   Baber, U ^b   Mehran, R ^a  

^a MOUNT SINAI HOSPITAL   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

Atherosclerosis; Inflammation; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE DIPHOSPHATE PLATELET RECEPTOR P2Y INHIBITOR; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; ANTICOAGULANT THERAPY; BARE METAL STENT; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CARDIOVASCULAR STENT; CORONARY ARTERY THROMBOSIS; DEVICE SAFETY; DRUG ELUTING STENT; DUAL ANTIPLATELET THERAPY; HEART DEATH; HEART INFARCTION; HUMAN; LONG TERM CARE; MEDICAL PRACTICE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SHORT COURSE THERAPY; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT WITHDRAWAL; DRUG COMBINATION; MYOCARDIAL INFARCTION; PROCEDURES; STENT; TIME;

ASPIRIN; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS; TIME FACTORS;

EID: 84904092165     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
2. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227-34. (Pubitemid 35373553)
3. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK et al. Stent anticoagulation restenosis study investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998; 339:1665-71. (Pubitemid 28550691)
4. Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215-22. (Pubitemid 26031477)
5. Albiero R, Hall P, Itoh A, Blengino S, Nakamura S, Martini G et al. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation 1997;95:1145-56. (Pubitemid 27097824)
6. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation 1998;98:1597-603. (Pubitemid 28500380)
7. Schomig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9. (Pubitemid 26120185)
8. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Pubitemid 32758501)
9. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P et al.; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;294:1224-32. (Pubitemid 41352110)
10. Holmes DR Jr, Kereiakes DJ, Laskey WK, Colombo A, Ellis SG, Henry TD et al. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol 2007;50:109-18. (Pubitemid 47007739)
11. Holmes DR Jr, Kereiakes DJ, Garg S, Serruys PW, Dehmer GJ, Ellis SG et al. Stent thrombosis. J Am Coll Cardiol 2010;56:1357-65.
12. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ et al.; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813-8.
13. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions Writting Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:156-75.
14. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C et al.; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91.
15. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA et al.; EVENT Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001-9.
16. Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv 2008;1:494-503.
17. Jensen LO, Maeng M, Thayssen P, Kaltoft A, Tilsted HH, Bøttcher M et al. Clinical outcome after primary percutaneous coronary intervention with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction. Circ Cardiovasc Interv 2008;1:176-84.
18. Garg P, Cohen DJ, Gaziano T, Mauri L. Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. J Am Coll Cardiol 2008;51:1844-53. (Pubitemid 351615257)
19. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41. (Pubitemid 46717966)
20. Nakazawa G, Vorpahl M, Finn AV, Narula J, Virmani R. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc Imaging 2009;2:625-8.
21. Douglas G, Van Kampen E, Hale AB, McNeill E, Patel J, Crabtree MJ et al. Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification. Eur Heart J 2013;34:3378-88.
22. Otsuka F, Finn AV, Yazdani SK, Nakano M, Kolodgie FD, Virmani R. The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol 2012;9:439-53.
23. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-81. (Pubitemid 43005183)
24. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-68. (Pubitemid 46089732)
25. Brar SS, Kim J, Brar SK, Zadegan R, Ree M, Liu IL et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol 2008;51:2220-7. (Pubitemid 351754993)
26. Lagerqvist B, Carlsson J, Fröbert O, Lindbäck J, Scherstén F, Stenestrand U, James SK; Swedish Coronary Angiography and Angioplasty Registry Study Group. Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry. Circ Cardiovasc Interv 2009;2:401-8.
27. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L; SCAAR Study Group. Long-term outcomes with drug-eluting stents versus baremetal stents in Sweden. N Engl J Med 2007;356:1009-19. (Pubitemid 46376801)
28. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bitd JA, Cercek B et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:e574-651.
29. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-55.
30. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78. (Pubitemid 46281313)
31. Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv 2008;1:494-503.
32. Faxon DP, Lawler E, Young M, Gaziano M, Kinlay S. Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study. Circ Cardiovasc Interv 2012;5:372-80.
33. Beinart SC, Kolm P, Veledar E, Zhang Z, Mahoney EM, Bouin O et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol 2005;46:761-9. (Pubitemid 41224796)
34. Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ; CREDO Investigators. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2009;157:369-74.
35. Cassese S, Byrne RA, Tada T, King LA, Kastrati A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J 2012;33:3078-87.
36. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T et al.; j-Cypher Registry Investigators. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012;125:584-91.
37. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-54. (Pubitemid 47255992)
38. Schulz S, Schuster T, Mehili J, Byrne RA, Ellert J, Massberg S et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing and relation to discontinuation of clopidogrel therapy over a 4 year period. Eur Heart J 2009;30:2714-21.
39. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505-13.
40. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C et al.; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015-26.
41. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R; PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J 2013;34:909-19.
42. Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C et al.; PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Investigators. Two-Year Outcomes After First- or Second-Generation Drug-Eluting or Bare-Metal Stent Implantation in All-Comer Patients Undergoing Percutaneous Coronary Intervention: A Pre-specified Analysis From the PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY (PRODIGY). JACC Cardiovasc Interv 2013 [In press].
43. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010;362:1374-82.
44. Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized controlled trial. Circulation 2013 [In press].
45. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG et al.; RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340-8.
46. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV et al.; for the OPTIMIZE Trial Investigators. Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents: The OPTIMIZE Randomized Trial. JAMA 2013;310:2510-22.
47. Kandzari DE, Barker CS, Leon MB, Mauri L, Wijns W, Fajadet J et al. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. JACC Cardiovasc Interv 2011;4:1119-28.
48. Kimura T, Toyofuku M, Morimoto T, Hayashi Y, Ueda H, Kawai K et al.; j-Cypher Registry Investigators. Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the j-Cypher registry. Circulation 2009;120:1866-74.
49. Tada T, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Byrne RA et al.; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. Circ Cardiovasc Interv 2012;5:381-91.
50. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21. (Pubitemid 39410418)
51. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-92. (Pubitemid 40814135)
52. Kerner A, Gruberg L, Kapeliovich M, Grenadier E. Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc Interv 2003;60:505-8. (Pubitemid 37466760)
53. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007;115:1440-55. (Pubitemid 46648381)
54. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008. (Pubitemid 46376800)
55. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-9. (Pubitemid 46376803)
56. James SK, Stenestrand U, Lindbäck J, Carlsson J, Scherstén F, Nilsson T et al.; SCAAR Study Group. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 2009;360:1933-45.
57. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-8. (Pubitemid 46328299)
58. Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 2005;45:995-8. (Pubitemid 40432428)
59. Kim BK, Shin DH, Kim JS, Ko YG, Choi D, Jang Y et al. Optical coherence tomography-based evaluation of malapposed strut coverage after drug-eluting stent implantation. Int J Cardiovasc Imaging 2012;28:1887-94.
60. Tanigawa J, Barlis P, Dimopoulos K, Dalby M, Moore P, Di Mario C. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. Int J Cardiol 2009;134:180-8.
61. Räber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012;125:1110-21.
62. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R et al.; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-74.
63. Kirtane AJ, Leon MB, Ball MW, Bajwa HS, Sketch MH Jr, Coleman PS et al.; ENDEAVOR IV Investigators. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. JACC 2013;6:325-33.
64. Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011;58:1569-77.
65. Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes D et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012;5:357-64.
66. Sarno G, Lagerqvist B, Fröbert O, Nilsson J, Olivecrona G, Omerovic E et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012;33:606-13.
67. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30. (Pubitemid 40617065)
68. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-9. (Pubitemid 44305292)
69. van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399-409.
70. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009;119:1634-42.
71. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714-22.
72. Anwaruddin S, Askari AT, Saudye H. Characterization of postoperative risk associated with prior drug-eluting stent use. JACC Cardiovasc Interv 2009;2:542-9.
73. Cruden NL, Harding SA, Flapan AD. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery. Circ Cardiovasc Interv 2010;3:236-42.
74. Berger PB, Kleiman NS, Pencina MJ. Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. JACC Cardiovasc Interv 2010;3:920-7.
75. Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009;53:1488-97.
76. Byrne RA, Schulz S, Mehilli J, Iijima R, Massberg S, Neumann FJ et al.; Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Investigators. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J 2009;157:620-4.
77. Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160:1035-41.
78. Helft G, Le Feuvre C, Georges JL, Carrie D, Leclercq F, Eltchaninoff H et al. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Trials 2013;14:56.